![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 2
2017
Chamie, Karim; Donin, Nicholas M.; Klöpfer, Pia; Bevan, Paul; Fall, Barbara; Wilhelm, Olaf; Störkel, Stephan; Said, Jonathan; Gambla, Michael; Hawkins, Robert E.; Jankilevich, Gustavo; Kapoor, Anil; Kopyltsov, Evgeny; Staehler, Michael; Taari, Kimmo; Wainstein, Alberto J. A.; Pantuck, Allan J. und Belldegrun, Arie S.
(2017):
Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma The ARISER Randomized Clinical Trial.
In: Jama Oncology, Bd. 3, Nr. 7: S. 913-920
2016
Powles, Thomas; Lackner, Mark R.; Oudard, Stéphane; Escudier, Bernard; Ralph, Christy; Brown, Janet E.; Hawkins, Robert E.; Castellano, Daniel; Rini, Brian I.; Staehler, Michael D.; Ravaud, Alain; Lin, Wei; O'Keeffe, Bridget; Wang, Yulei; Lu, Shan; Spoerke, Jill M.; Huw, Ling-Yuh; Byrtek, Michelle; Zhu, Rui; Ware, Joseph A. und Motzer, Robert J.
(2016):
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.
In: Journal of Clinical Oncology, Bd. 34, Nr. 14:
1660-U204